#NVS

Lead report

Novartis wins full FDA approval for Fabhalta in IgAN (NVS:NYSE)

Novartis (NVS) wins full FDA approval for the kidney disease drug, Fabhalta, to slow kidney function decline in adults with primary IgA nephropathy. Read more here.